Hypersensitivity Pneumonitis
Conditions
Interventions
Internal cleaning of air conditioners by cleaners Installation of air purifiers Patient and family education by doctors and nurses
Conventional antigen avoidance guidance by attending physician
Sponsors
Institute of Science Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with a history of hospital visit or hospitalization between April 1, 2023 and March 31, 2025 at the Department of Respiratory Medicine, Institute of Sciece Tokyo Hospital and the collaborating institutions (Ome Municipal General Hospital, Hiratsuka Kyosai Hospital, Yamanashi Prefectural Central Hospital, Japanese Red Cross Musashino Hospital, Tsuchiura Kyodo General Hospital, Tokai University Hospital, Kanagawa Cardiovascuiar and Respiratory Center), Patients who have been diagnosed with hypersensitivity pneumonia (low-confidence cases or higher in the Hypersensitivity Pneumonia Clinical Practice Guidelines 2022) and whose causative antigen is presumed to be avian or fungi/bacteria in the residence. In addition, patients who meet the following criteria will be considered The investigator determines that the disease is not associated with hypersensitivity pneumonitis at the time of screening and is expected to have a life expectancy of at least 24 months. Patients who are willing and able to comply with the prescribed study protocol for treatment and evaluation during the study period.
Exclusion criteria
Exclusion criteria: Minors Patients who are judged by the principal investigator/researcher to be ineligible for participation in the study Patients for whom respiratory function tests cannot be performed Use of certain doses of steroids, cyclosporine A, or tacrolimus at doses greater than 10 mg/day of prednisolone equivalent within 4 weeks prior to screening and planned during the study period Pregnancy or planned pregnancy during the study period Patients who refused to participate in the study Patients who are smoking at the time of inclusion Patients who have no air conditioning in their residence Patients who plan to move within 1 year or relocate for more than 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in change in environmental antigen levels between the two groups from the start of the study to 52 weeks Difference in change in effort lung capacity (FVC) and %FVC between the two groups from the start of the study to 52 weeks | — |
Countries
Japan
Contacts
Public ContactTsukasa Okamoto
Institute of Science Tokyo The Center for Personalized Medicine for Healthy Aging
Outcome results
None listed